Note 5. Segment Reporting (Segments Statements of Operations) (Details) (USD $)	3 Months Ended		9 Months Ended
	Mar. 31, 2013	Mar. 31, 2012	Mar. 31, 2013	Mar. 31, 2012
Segment Reporting Information [Line Items]
Product revenue	$ 2,724,740	$ 3,098,077	$ 8,635,078	$ 8,690,589
Revenues, net	2,724,740	3,098,077	8,635,078	8,690,589
Cost of goods sold	1,337,442	1,498,675	4,309,894	4,185,001
Marketing, general and administrative	1,409,274	1,562,831	4,303,775	4,482,491
Research and development	272,889	300,370	803,256	730,447
Total costs and expenses	3,019,605	3,361,876	9,416,925	9,397,939
Loss from operations	(294,865)	(263,799)	(781,847)	(707,350)
Loss (gain) on sales of assets	2,717,069
Equity in OTM	11,033	(532)	79,770	612
Interest Expense	0	(75,203)	(79,479)	(243,772)
Total other (expense) income	11,104	(75,718)	423	(243,060)
Income (Loss) from Continuing Operations before Income Taxes, Extraordinary Items, Noncontrolling Interest	(283,761)	(339,517)	(781,424)	(950,410)
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest		(340,000)
Income taxes benefit from continuing operations		0	0	0
Net (loss) from continuing operations	(283,761)	(339,517)	(781,424)	(950,410)
Income (Loss) from Continuing Operations Attributable to Parent		(339,517)
Sonomed-Escalon [Member]
Segment Reporting Information [Line Items]
Product revenue	2,724,740	3,098,077	8,635,078	8,690,589
Revenues, net	2,724,740	3,098,077	8,635,000	8,691,000
Cost of goods sold	1,337,442	1,498,675	4,309,894	4,185,001
Marketing, general and administrative	1,339,879	1,468,733	4,022,842	4,157,500
Research and development	272,889	300,370	803,256	730,447
Total costs and expenses	2,950,000	3,268,000	9,136,000	9,073,000
Loss from operations		(169,701)	(501,000)	(382,000)
Equity in OTM	0	0	0	0
Interest Expense	0	0	0	0
Total other (expense) income	0	0	0	0
Income (Loss) from Continuing Operations before Income Taxes, Extraordinary Items, Noncontrolling Interest			(501,000)	(382,359)
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest		(170,000)
Income taxes benefit from continuing operations	0	0	0	0
Net (loss) from continuing operations			(500,914)	(382,359)
Income (Loss) from Continuing Operations Attributable to Parent		(169,701)
Corporate [Member]
Segment Reporting Information [Line Items]
Product revenue	0	0	0	0
Revenues, net	0	0	0	0
Cost of goods sold	0	0	0	0
Marketing, general and administrative	69,395	94,098	280,933	324,991
Research and development	0	0	0	0
Total costs and expenses	69,000	94,000	281,000	325,000
Loss from operations	(69,395)	(94,098)	(281,000)	(325,000)
Equity in OTM	11,000	(1,000)	79,770	612
Interest Expense	0	(75,203)	(79,479)	(243,772)
Total other (expense) income	11,104	(75,718)	423	(243,060)
Income (Loss) from Continuing Operations before Income Taxes, Extraordinary Items, Noncontrolling Interest			(280,510)	(568,051)
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest	(58,000)	(170,000)
Income taxes benefit from continuing operations	0	0	0	0
Net (loss) from continuing operations			(280,510)	(568,051)
Income (Loss) from Continuing Operations Attributable to Parent	$ (58,291)	$ (169,816)